OBJECTIVES: To establish incidence rates and risk factors for HIV-associated oral candidiasis (OC), oral hairy leukoplakia (OHL), and any HIV-associated oral diseases (HIV-OD). DESIGN: This prospective, cumulative case-control study followed 283 initially oral disease-free HIV-1-infected men and women for 2 years. Incidence rate ratios (IRR) and incidence proportions for OC, OHL, and HIV-OD were estimated. Multivariable analyses using Poisson regression determined the most parsimonious best-fitting model explaining the outcomes. RESULTS: Incidence rate (per 1000 person-months) was 9.3 for OC, 6.8 for OHL, and 13.5 for HIV-OD. Incidence of OC was associated with low CD4 count (adjusted IRR = 3.0 (95% CI = 1.7, 5.1)), smoking (IRR = 1.9 (1.0, 3.8)) and combination antiretroviral therapy (IRR = 0.3 (0.1, 0.8)). Incidence of OHL was associated with low CD4 count, conditional upon smoking status. Conclusions Low CD4 count and smoking are important risk factors for HIV-associated OC and OHL. Antiretroviral medications are protective for OC but not for OHL.
OBJECTIVES: To establish incidence rates and risk factors for HIV-associated oral candidiasis (OC), oral hairy leukoplakia (OHL), and any HIV-associated oral diseases (HIV-OD). DESIGN: This prospective, cumulative case-control study followed 283 initially oral disease-free HIV-1-infectedmen and women for 2 years. Incidence rate ratios (IRR) and incidence proportions for OC, OHL, and HIV-OD were estimated. Multivariable analyses using Poisson regression determined the most parsimonious best-fitting model explaining the outcomes. RESULTS: Incidence rate (per 1000 person-months) was 9.3 for OC, 6.8 for OHL, and 13.5 for HIV-OD. Incidence of OC was associated with low CD4 count (adjusted IRR = 3.0 (95% CI = 1.7, 5.1)), smoking (IRR = 1.9 (1.0, 3.8)) and combination antiretroviral therapy (IRR = 0.3 (0.1, 0.8)). Incidence of OHL was associated with low CD4 count, conditional upon smoking status. Conclusions Low CD4 count and smoking are important risk factors for HIV-associated OC and OHL. Antiretroviral medications are protective for OC but not for OHL.
Authors: Marcel A de Dios; Cassandra A Stanton; Miguel Ángel Cano; Elizabeth Lloyd-Richardson; Raymond Niaura Journal: Nicotine Tob Res Date: 2015-06-26 Impact factor: 4.244
Authors: Chunmei C Wang; Luis C Yepes; Robert J Danaher; Joseph R Berger; Yunanan Mootoor; Richard J Kryscio; Craig S Miller Journal: Oral Surg Oral Med Oral Pathol Oral Radiol Endod Date: 2010-02
Authors: Pankaj Chaudhary; Kanika Manral; Rahul Gupta; Aroon Kamal Singh Bengani; Bhumit Ishvarlal Chauhan; Deepanshu Arora Journal: J Family Med Prim Care Date: 2020-07-30
Authors: Patricia I Diaz; Bo-Young Hong; Amanda K Dupuy; Linda Choquette; Angela Thompson; Andrew L Salner; Peter K Schauer; Upendra Hegde; Joseph A Burleson; Linda D Strausbaugh; Douglas E Peterson; Anna Dongari-Bagtzoglou Journal: J Fungi (Basel) Date: 2019-06-13